Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People whose general health and ability to carry out daily activities meets a minimum level, as assessed by standard medical scoring tools (confirm with trial site)
- People whose heart, liver, kidneys, and other organs are functioning well enough to receive standard immunotherapy treatment, as determined by their treating cancer doctor
- People who are planning to receive, and are able to receive, a specific type of immunotherapy called a PD-1 or PD-L1 checkpoint inhibitor as part of their standard cancer care throughout the study — other standard immunotherapy or chemotherapy given alongside this may also be permitted
- People who have been diagnosed with Non-Small Cell Lung Cancer (a type of lung cancer) or Melanoma (a type of skin cancer), confirmed by a tissue sample (biopsy)
- People who have cancer that has spread to the liver, confirmed by scans or imaging
- People who are able to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) before and during the study, where applicable
- People who are able to understand the study and are willing to sign a consent form — a legally authorised representative may sign on a participant's behalf if needed
- People whose health insurance has approved coverage for the radiotherapy treatment involved in the study before treatment begins
Who may not be able to join:
- People with Non-Small Cell Lung Cancer or Melanoma who received immunotherapy after surgery (adjuvant immunotherapy) within the 6 months before enrolling in the study
- People with Non-Small Cell Lung Cancer who have certain specific genetic changes in their cancer cells (known as EGFR, ALK, ROS1, or RET mutations) — this applies to one specific group within the trial (confirm with trial site)
- People with other serious or uncontrolled medical conditions that the study doctor believes would make participation unsafe
- People with another current or past cancer that could affect the safety of the study or make it difficult to assess how well the treatment is working, in the opinion of the study doctor
- People who are pregnant, due to the use of radiation therapy in this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 513-584-7698
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression free survival (PFS) measured by 6-month PFS for each cohort compared separately to historical trials with an effect size goal of 25% improvement in 6-month PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.